Key facts
- It has raised $71.1M; the latest was Early Stage VC in Sep 2025.
- Notable investors include Hankang Capital, Lepu Medical, Tencent Holdings, Trinitas Capital (Beijing).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Minwei Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Minwei Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Minwei Biotechnology
Developer of multi-core macromolecule biopharmaceuticals targeting multiple pipelines. The company focuses on endocrine, metabolic diseases and their complications, cardiovascular and other fields, and develops recycling antibodies, which can reduce the clinical dosage of drugs, significantly extend the medication interval, enabling patients to reduce the medical burden.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- minweibiotech.cn/
- Ownership
- Privately Held (backing)
Minwei Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Minwei Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Minwei Biotechnology in its N-PORT filings yet. We sweep new filings monthly.